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The interaction between the EF-hand Ca2+-binding protein calmyrin and presenilin 2 (PS2) has been suggested to play a role in Alzheimer’s
disease (AD). We now report that calmyrin binds specifically endogenous PS2 and not PS1. However, binding appears to be Ca2+-independent and
calmyrin does not exhibit a Ca2+-dependent translocation to intracellular membranes as demonstrated in a Ca2+-myristoyl switch assay. Moreover,
calmyrin is only present at very low levels in brain areas associated with the onset of AD. In rat, forebrain calmyrin is localized only in a subset of
principal neurons, similarly as in human forebrain. Finally, subcellular fractionation demonstrates only a limited overlap of calmyrin and PS2 at
neuronal membranes. We therefore conclude that calmyrin will not contribute significantly as a Ca2+-sensor that transduces Ca2+-signaling events
to PS2 in forebrain.
D 2005 Elsevier B.V. All rights reserved.Keywords: EF-hand calcium-binding protein; Calmyrin; CIB1; KIP1; Presenilin 2; Alzheimer’s disease1. Introduction
The pathogenesis of AD is associated with loss of neurons
in limbic and cortical regions of forebrain, characterized by
extracellular deposits of insoluble h-amyloid peptide (Ah)
called senile plaques and intracellular aggregates composed
mainly of the cytoskeletal tau protein known as neurofibrillary
tangles. Another feature of the disease is dysregulation of
intracellular Ca2+-signaling events [1,2]. Accordingly, a variety
of neuronal Ca2+-binding proteins including calsenilin, sorcin,
calmyrin, and calp/kchip4 [3–6] have been identified that
potentially can trigger altered Ca2+-signaling pathways to key
molecules for the onset of the disease. Such molecules include
presenilins (PS1 and PS2), which are integral membrane
protein components of g-secretase complexes responsible for0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2005.09.006
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E-mail address: ulawojda@iimcb.gov.pl (U. Wojda).the generation of h-amyloid peptides as well as for the
intramembranous proteolysis of other proteins [7]. Presenilins
by themselves can regulate intracellular Ca2+-concentrations.
Part of this scheme is the idea that intracellular Ca2+-levels will
regulate these interactions and that a disturbance in Ca2+
homeostasis underlie neurodegeneration [2]. Unfortunately,
however, the molecular underpinnings for most of these
interactions are not clear.
The Ca2+-binding protein calmyrin, also termed CIB [8] or
KIP [9] has been shown to interact with PS2 and it was
suggested that this interaction might play a role in the
pathogenesis of AD [5]. Along these lines, we have recently
investigated the distribution of calmyrin in human forebrain
during normal aging and in AD [10]. Calmyrin was found to be
present in a subset of forebrain neurons and also accumulated
in senile plaques, hallmarks of AD [10]. Immunostainings and
Western blot analyses, however, indicated that calmyrin is not a
particularly abundant neuronal protein in the brain regions
affected in AD [10]. To learn more about the nature of itsta 1762 (2006) 66 – 72
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whether binding to PS2 is Ca2+-dependent and tried to identify
cellular and subcellular structures in the rat brain where the
proposed interaction could happen in vivo.
2. Materials and methods
2.1. Antibody production
Recombinant calmyrin was generated as described previously [10]. Purified
protein was used to generate two anti-calmyrin polyclonal antisera in rabbits
(Innovagen, Sweden, and Biogenes, Germany). The antiserum from Biogenes
was affinity-purified using standard technology and employed for immunohis-
tochemical analyses.
2.2. Calmyrin affinity chromatography
Recombinant calmyrin (10 mg) was covalently attached to cyanogen
bromide activated Sepharose 4B (Fluka) according to the manufacturer’s
instructions. Immortalized human lymphocytes were grown in RPMI supple-
mented with 10% FBS. Cells were homogenized in 20 mM Tris–HCl, pH 7.5,
1 mM 2-mercaptoethanol (2-ME), and protease inhibitor cocktail (Roche) with
a Dounce homogenizer and centrifuged at 1000g for 15 min at 4 -C. The
supernatant was homogenized again and centrifuged at 100,000g for 1 h at 4
-C. The resulting supernatant was centrifuged again at 100,000g for 1 h at 4
-C and both pellets were combined. This crude lymphocyte membrane fraction
was solubilized in buffer A (20 mM Tris–HCl, pH 7.5, 1% CHAPS, 0.1 mM
CaCl2 or 2 mM EGTA, 1 mM 2-ME, Roche protease inhibitor cocktail), spun at
100,000g for 1 h at 4 -C and the supernatant was applied to the column
equilibrated with the same buffer. Elution of proteins was monitored by
continuous absorbance measurements at 280 nm. The flow-through, a fraction
eluted with buffer A supplemented with 150 mM NaCl (buffer B), followed by
the fraction eluted with the buffer B supplemented with 2 mM EGTA (only in
the presence of 0.1 mM CaCl2) and finally with buffer B supplemented with 1
M NaCl were concentrated (Vivaspin, Sigma), and analyzed by SDS-PAGE and
immunoblotting.
2.3. Pull-down assay
HeLa cells were lysed in TBS, pH 7.5, 0.3% Triton X-100, complete
inhibitor cocktail (Roche), and 2 mM EGTA or 0.1 mM CaCl2 for 1 h at
4 -C and centrifuged at 23,600g for 30 min. 600 Al of the supernatant
containing ¨0.5 mg total protein were incubated overnight at 4 -C with 4
Ag of recombinant calmyrin covalently attached to Sepharose 4B
according to manufacturer’s instruction (Fluka). After extensive washing
with TBS, SDS-PAGE sample buffer was added to the matrix to a final
amount of 60 Al. 20 Al of the pull-down fraction were subjected to
Western blotting.
2.4. Transfection and coimmunoprecipitation
For transient transfection, the pCaMy EGFP N1 or pEGFP N1 plasmid (4
Ag, Clontech) was transfected with Polyfect reagent (Qiagen) according to
the manufacturer’s protocol into COS-7 cells seeded in 10 cm plates. Two
days after transfection, cells were harvested in TBS and centrifuged at
600g at 4 -C for 5 min. The supernatant was discarded and the pellet was
homogenized in the lysis buffer (TBS, pH 7.5, 0.2% Triton X-100, 2 mM
EGTA, complete inhibitor cocktail (Roche)). The lysed cells were incubated
on ice at 4 -C for 1 h and centrifuged at 11,500g at 4 -C for 30 min to
remove cell debris. Aliquots of cell lysates were precleared with Sepharose A
(Amersham) at 4 -C for 30 min and then immunoprecipitated using rabbit
polyclonal antibodies anti-GFP (Abcam) and anti-PS2 (NTF, Sigma). Normal
rabbit IgG (Santa Cruz) was used as a negative control. After overnight
incubation at 4 -C and extensive washing with TBS, SDS-PAGE sample
buffer was added, samples were separated on 5–20% gradient gels and
analysed by Western blotting.2.5. Isolation of subcellular protein fractions from rat brain
Brains from 16 adult rats were homogenized with Dounce homogenizer (12
strokes at 900 rpm) in 10 ml/l homogenization buffer (5 mM HEPES, pH 7.4,
320 mM sucrose, and protease inhibitor cocktail from Roche). Cell debris and
nuclei were removed by 1000g centrifugation and the supernatant was spun
for 20 min at 13,000g, resulting in the supernatant and the pellet P2 (crude
membrane fraction). The P2 pellet was homogenized with Dounce homoge-
nizer and fractionated by centrifugation at 85,000g for 2 h at 4 -C in a sucrose
step gradient (0.85/1.0/1.2 M Sucrose). Myelins, microsomes, and synapto-
somes were separated and collected. For isolation of the synaptic membranes
containing synaptic junctional proteins, the synaptosomal fraction was
incubated with 1 mM Tris–HCl, pH 8.1 (hypo-osmotic shock) for 30 min at
0 -C and centrifuged for 30 min at 33,000g. After centrifugation, the pellet
containing synaptosomal membranes was collected. SDS-PAGE sample buffer
was added to the all collected subcellular fractions which were next analyzed
by Western blotting with anti-calmyrin and anti-PS2 antibodies.
2.6. Western blot analysis
Protein extracts of lymphocytes, HeLa cells and COS-7 cells were obtained
as described above. Homogenates of different rat tissues and subcellular
membrane fractions were subjected to Western blotting as described previously
[10]. Anti-calmyrin antibodies were diluted 1:3000, antibodies against N- and
C-terminus of PS2 (Sigma) and PS1 (R&D System) were diluted 1:200 and
1:500, respectively. Mouse anti-GFP polyclonal antibody (Babco) was diluted
1:5000. Detection was performed with the ECL detection kit (Amersham).
2.7. Ca2+-myristoyl switch assay
COS-7 cells were grown on poly-d-lysine coated glass coverslips to 50–
70% confluency. Transient transfection was done as described above. Time-
lapse microscopy of COS-7 cells was performed two days after transfection as
described previously [11]. Translocation of VILIP-1-GFP or calmyrin-GFP was
monitored after raising the intracellular calcium concentration by addition of 2
AM ionomycin (Calbiochem).
2.8. RT-PCR
Perfused adult rat brains were dissected and mRNA extracted according to
the manufacturer’s protocol (Oligotex, Qiagen). Due to the low abundance of
the calmyrin transcript in brain, mRNA was reverse transcribed using random
primers and a 3V-calmyrin gene-specific primer (Sensiscript Reverse Transcrip-
tion, Qiagen). PCR amplification was performed using Taq DNA polymerase
(Qiagen) and calmyrin-specific primers (Forward primer: 5V atg gga ggt tcg ggc
agt cgc 3V, reversed primer: 5V cag gac aat ctt aaa gga agc tgg 3V). PCR
conditions: 40 cycles with annealing at 58 -C, 30 s; extension at 72 -C, 1 min;
denaturation at 95 -C, 2 min, and final extension at 72 -C, 5 min.
2.9. Animals and immunostainings of rat brain sections
12-week-old male Wistar rats kept under normal laboratory conditions (a
12-12 h dark-light cycle at a relative humidity of 50–60% and 22 -C with food
and water available) were used in an institutional review-board approved
protocols. Different areas of rat brain without perfusion were frozen for Western
blots. Other rats were transcardially perfused with PBS followed by 4%
formaldehyde in PBS. Perfused brainswere dissected, fixed by 4% formaldehyde
in PBS, embedded in 30% sucrose, and serial sections cut in cryostat were
subjected to immunohistochemical staining. Immunocytochemical labeling of
calmyrin, PS2, and MAP2 was performed according to standard diaminobenzi-
dine/nickel immunoperoxidase protocols as described previously [12]. Primary
antibody [rabbit anti-calmyrin antibody affinity purified (1:100 and 1:1000),
rabbit anti-PS2 antibody (Sigma, 1:100), and mouse anti-MAP2 antibody
(Sigma, 1:1000)] were diluted in 10% normal goat serum, 0.3% Triton X-100
supplemented with 0.1% NaN3 and incubated for 24 h at 4 -C. The specificity of
the immunoreaction was controlled by incubation with buffer and omitting the
primary antibody (no staining was observed). Additionally, antibody against
A 21 3
-calmyrin (22 kDa)
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Fig. 1. PS2 binds to calmyrin in a Ca2+-independent manner. (A) PS2 and
calmyrin are present in human lymphocyte membranes. Western blots were
developed with anti-calmyrin antibody (upper panel) or anti-PS2 antibody
(lower panel). 1) recombinant calmyrin (1 ng), 2) supernatant after centrifu
gation at 1000g, 3) pellet after centrifugation at 100,000g (crude membrane
fraction). Equal amounts of protein (30 Ag) were loaded in each lane. (B) PS2
from human lymphocytes is retarded on a calmyrin-affinity column in a Ca2+
independent manner. The solubilized lymphocyte membrane fraction was
applied on a calmyrin-Sepharose column in (a) 0.1 mM CaCl2 or (b) 2 mM
EGTA. Eluted fractions were analyzed by Western blotting: (1) input, (2
unbound fraction, (3) fraction eluted with 150 mM NaCl, (4) fraction eluted
with 2 mM EGTA, (5) fraction eluted with 1 M NaCl. Western blots were
developed with anti-PS2 antibody (upper row) and anti-PS1 antibody (lowe
row). (C) Endogenous PS2 from HeLa cells is pulled down by recombinan
calmyrin in a Ca2+-independent manner. Western blotting with anti-PS2
antibody of HeLa cell lysate was performed from experiments done either in
the presence of 0.1 mM CaCl2 or 2 mM EGTA. Depicted is the input (1, 2) and
the bound protein (3, 4) either to Sepharose 4B (1, 3) or calmyrin-Sepharose 4B
(2, 4). (D) Recombinant calmyrin pull downs endogenous C-terminal fragmen
of PS2 (PS2 CTF) but not of PS1 from HeLa cells. Western blotting with C
terminal-specific anti-PS2 (left panel) and anti-PS1 (right panel) antibodies was
performed following the pull-down experiments done in the 2 mM EGTA
presence in HeLa cell lysate. (1) input, (2) wash fraction, (3) protein fraction
bound to calmyrin-Sepharose 4B.3. Results
3.1. Calmyrin binds to endogenous PS2 in a Ca2+-independent
manner
Western blot comparison of calmyrin expression level in
main parts of rat brain and in human blood cells suggested that
lymphocyte membranes contain high amounts of both calmyrin
and PS2 (Fig. 1A) and are easily accessible. We have therefore
chosen these cells to characterize the Ca2+-requirements for
binding of endogenous PS2 to calmyrin. The solubilized
lymphocyte membrane fraction containing PS2 was transferred
to calmyrin-affinity resin. Affinity chromatography of solubi-
lized proteins from the membrane fraction showed that PS2
was retarded on the calmyrin-bound resin (Fig. 1B). Notewor-
thy, PS1 did not bind to the calmyrin-affinity column (Fig. 1B),
indicating that the PS2/calmyrin interaction was specific. In the
presence of 0.1 mM Ca2+, endogenous PS2 was retained on the
column, and was not released in the presence of the Ca2+
chelator EGTA until a buffer of high ionic strength was used
(Fig. 1B). PS2 from the solubilized membrane fraction bound
to the calmyrin-resin also in the presence of EGTA and was
only eluted in the presence of 1 M NaCl (Fig. 1B). Thus,
although the specific interaction between calmyrin and native
PS2 could be confirmed, these data suggest that the binding is
not Ca2+-dependent. Also, no difference in binding to wild type
PS2 and PS2 with recently identified mutation Q228L [13] was
observed (data not shown). To further substantiate these
observations, we performed calmyrin/PS2 pull-down assays.
Sepharose-coupled calmyrin pulled down endogenous PS2
from HeLa cells while matrix without calmyrin did not (Fig.
1C). Binding of PS2 occurred both in the presence of 0.1 mM
Ca2+ and 2 mM EGTA, suggesting that Ca2+ concentrations do
not regulate the PS2/calmyrin binding. In addition, we referred
to the previous report that calmyrin interacts with the loop
region located in the C-terminal part of PS2 in Yeast 2 Hybrid
assay [5]. As PS1 and PS2 exist in the cell not only as
holoproteins, but also as their N-terminal and C-terminal
peptides, we have analyzed Ca2+ requirements of calmyrin
binding to the endogenous C-terminal PS2 fragment (PS2
CTF). As depicted in Fig. 1D, calmyrin pulled-down PS2 CTF
in the presence of EGTA while PS1 CTF was not bound. This
experiment sustains additional verification of the specific,
Ca2+-independent interaction of recombinant calmyrin with the
endogenous C-terminal peptide of PS2.
Further evidence for the existence of calmyrin/PS2 com-
plexes in the absence of Ca2+ in the cell was provided by the
coimmunoprecipitation assay performed in COS-7 cells. As
shown in Fig. 2A, endogenous PS2 levels in COS-7 cells are
rather high. Since calmyrin expression in these cells was
undetectable, we transiently transfected COS-7 cells with GFP
or calmyrin-GFP coding plasmid providing free N-terminal
calmyrin end for myristoylation (intracellular myristoylation of-
-
)
r
t
t
-calmyrin-transfected cells was demonstrated previously in [5]).
Cell lysates prepared in the presence of 2 mM EGTA were
subjected to immunoprecipitation (Fig. 2B, C). In this
experiment, anti-PS2 antibody coimmunoprecipitated cal-
myrin-GFP and not GFP, suggesting specific calmyrin/PS2
interaction which occurs in the absence of Ca2+. Control
Fig. 3. In contrast to VILIP-1 calmyrin does not show a translocation in
transfected COS-7 cells upon a Ca2+-raising stimulus. COS-7 cells were
transiently transfected with calmyrin-GFP (A, B), or VILIP-1-GFP (C, D). (A)
COS-7 cells expressing calmyrin-GFP before stimulation and (B) 2 min after
raising the intracellular calcium concentration by addition of 2 AM ionomycin.
(C) COS-7 cells expressing VILIP-1-GFP before and (D) 2 min after addition
of 2 AM ionomycin. Scale bar=30 Am.
A
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Fig. 2. Calmyrin coimmunoprecipitates with endogenous PS2 in the absence of
Ca2+. (A) Western blot of control COS-7 cellular lysate developed with anti-
PS2 antibody. (B, C) Lysates prepared in the presence of 2 mM EGTA from
COS-7 cells transiently transfected with GFP (B) or calmyrin-GFP (C) were
immunoprecipitated (IP) with rabbit antibody anti-GFP or anti-PS2 as
described under Materials and methods. Normal rabbit IgG was used as a
negative control. Immunoprecipitates were next analyzed by Western blot with
mouse anti-GFP antibody. Lysates prepared from transfected COS-7 cells
without immunoprecipitation were used as a control for the migration pattern of
GFP and calmyrin-GFP. The same amount of protein extracts (30 Ag) were
loaded in each line.
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tion did not result in GFP or calmyrin immunoprecipitation,
confirming that the interaction between calmyrin and PS2 is
specific. Among various attempts of calmyrin/PS2 coimmuno-
precipitation undertaken by others, so far only one assay, based
on the detection of 3H-myristoylated calmyrin in cotransfected
HeLa cells, proved successful [5]. Our data provide therefore
first evidence that intracellular calmyrin has the ability to
interact with physiological levels of PS2 and that this
interaction does not require Ca2+.
3.2. Calmyrin does not exhibit a Ca2+-myristoyl switch
Studies on recoverin have shown that the myristoyl group is
sequestered in the Ca2+-free form of the protein and following
Ca2+-binding extrusion of the myristoyl group follows the
substantial conformational change in the EF-hand structures
[14]. This so-called Ca2+-myristoyl switch is thought to be a
mechanism for anchoring Ca2+-binding proteins to intracellular
and plasma membranes in response to elevated Ca2+ levels.
Calmyrin has been shown to be myristoylated at its N-terminus
[5], and a Ca2+-dependent translocation to intracellular
membranes might provide another mechanism for a Ca2+-
dependent trigger of a target interaction with PS2. To test this
possibility, we transfected COS-7 cells with a wild-type
calmyrin–GFP fusion protein. As a positive control, we used
a similar VILIP-1 construct, a neuronal calcium sensor protein,
for which a Ca2+-myristoyl switch as a mechanism for a Ca2+-mediated translocation to cellular membranes has been
documented [11]. Accordingly, the translocation of VILIP-1-
GFP could be confirmed in COS-7 cells after stimulation with
2 AM ionomycin (Fig. 3C, D). In contrast, no translocation to
membranes was seen in response to ionomycin stimulation in
calmyrin–GFP transfected cells (Fig. 3A, B). Thus, the
postulated function of calmyrin as a Ca2+-dependent sensor
triggering Ca2+ signals to PS2 seems also not supported by a
Ca2+-myristoyl switch within the intramolecular structure of
calmyrin.
3.3. Calmyrin is of low abundance in rat forebrain and its
expression in subcellular membranes shows limited overlap
with PS2
Western blotting and RT-PCR experiments confirmed the
presence of calmyrin in rat brain areas (Fig. 4A, B). However,
the protein expression level compared to h-actin seems to be
lower than in some other tissues and lower than PS2 level.
Calmyrin subcellular localization in rat brain membranes
showed limited overlap with that of PS2 and particularly its
low levels were detected in synaptosomes (Fig. 4C).
Since the onset of AD is associated with functional and
structural changes in the forebrain, we examined the distribu-
tion of calmyrin in more details by means of immunohisto-
chemistry in this brain region. As reported previously for
human brain [10], staining of a subset of pyramidal neurons
was observed in rat cortices (Fig. 5A). As compared to the
staining pattern obtained with PS2 or MAP2, the immunolabel
was, however, much more restricted (Fig. 5A–C), indicating
that the vast majority of cortical neurons do not express
Fig. 5. Immunostainings of rat brain. (A, D–I) anti-calmyrin antibody, (B) anti-MA
hippocampus, pyramidal neurons, (G) cortex, negative control (after preabsorption o
seen), (F) cerebellum, Purkinje cells, (H) medulla, neurons, (I) cerebellum, deep cer
Scale bar in A–C, E, G=80 Am, D=160 Am, F, H=20 Am, I=50 Am.
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Fig. 4. Distribution of calmyrin and PS2 in rat brain and in brain subcellular
membrane fractions. (A) Western blot of rat multiple tissue (left) and brain
areas (right) developed with anti-calmyrin and anti-PS2 antibodies. Anti-h-
actin antibody was used as a control. The same preparations of tissues were
used for all compared antibodies. (B) RT-PCR using templates from different
brain regions, and positive and negative controls. (C) Western blot of (a)
anti-calmyrin antibody, (b) anti-PS2 antibody. 1) crude membranes, 2)
myelins, 3) microsomes, 4) synaptosomes, 5) synaptosomal membranes, 6)
total homogenate. 30 Ag protein were loaded in each lane on all Western
blots.
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(Fig. 5D, E). Interestingly, in contrast to the human cerebellum,
calmyrin-immunolabel was also present in Purkinje cells and
deep cerebellar nuclei of rat brain (Fig. 5F, I). The most intense
neuronal calmyrin staining in rat brain was found in neurons of
medulla, where somata, neurites, and axonal processes were
labelled (Fig. 5H).
4. Discussion
In the present study, we have shown that calmyrin binds to
PS2 but not to PS1 and that this interaction appears to be Ca2+-
independent, what suggests it will largely depend on local
protein levels. However, no Ca2+-induced translocation of
calmyrin to intracellular membranes indicative for a Ca2+–
myristoyl switch was observed. Moreover, the calmyrin/PS2
interaction was originally identified in a Yeast 2 Hybrid screen
[5], a protein–protein interaction assay where N-terminal
myristoylation is not involved. Accordingly, we also found in
the present study binding of endogenous PS2 holoprotein and
its separate C-terminal peptide to recombinant non-myristoy-
lated calmyrin. These data implicate that the interaction with
PS2 is not dependent on the presence of a myristic acid in
calmyrin’s N-terminal part. Moreover, coimmunoprecipitation
of endogenous PS2 with calmyrin in the absence of Ca2+
suggests that calmyrin myristoylation does not change lack of
Ca2+ requirements for calmyrin binding to PS2. Finally, in
agreement with our previous data in human [10], calmyrin
transcript and protein levels in rat forebrain proved to be very
low and its subcellular localization differs from that of PS2. We
therefore conclude that calmyrin is not a major Ca2+-sensor for
PS2 in the forebrain neurons and in proposed scheme of Ca2+-
dysregulation during the onset of AD.
Recently, Zhu et al. [15] reported that point mutations of
crucial residues for Ca2+-binding in calmyrin’s EF-hands 3P2 antibody (C) anti-PS2 antibody; (A–C) cortex, pyramidal neurons, (D, E)
f anti-calmyrin antibody with recombinant calmyrin protein no staining can be
ebellar nuclei. Arrows indicate the most prominently stained cellular structures.
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experiments have to be, however, taken with some caution.
EF-hand surfaces are not only high-affinity binding sites for
Ca2+, but are concomitantly interfaces for protein–protein
interactions. Thus, deleting acidic surface exposed amino acids
does not exclusively affect Ca2+-binding, but will also
interfere with protein–protein interactions irrespective of the
bound Ca2+ ion. A variety of basic and hydrophobic a-helical
binding structures have been identified that confer to this
scenario (see for instance [16]).
Calmyrin ability to bind with its cellular target in a Ca2+-
independent manner seems not only restricted to PS2, but was
also recently demonstrated for calmyrin interaction with the
cytoplasmic domain of platelet integrin aIIb [17]. Target
binding of calmyrin independent of an intracellular Ca2+
stimulus distinguishes this protein from many related Ca2+-
sensors, but is not unique in this protein family; some protein
interactions of typical Ca2+-sensors like calmodulin or
caldendrin are also controlled by other means than intracel-
lular Ca2+-levels [18,19]. Similarly, calmyrin binding with
PS2 may not be constitutive in vivo but regulated, for
example, by other proteins that are known to associate with
PS2 overlapping calmyrin binding site in the C-terminal PS2
fragment. Such protein interactions seem to underlie involve-
ment of PS2 in vital cellular processes including apoptosis
and Ca2+ homeostasis [20], so the cross-talk between these
processes may determine availability of PS2 pools for its
binding partners. As the dissociation of other PS2 target
proteins might be a prerequisite to PS2/calmyrin interaction,
such scenario would explain lack of requirements for prior
calmyrin translocation to the membranes observed in our
studies. Moreover, while the paradigm of Ca2+-dependent
binding seems not applicable to calmyrin/PS2 complex
formation, some Ca2+-dependent regulation of the preformed
calmyrin/PS2 is not excluded and seems probable in the light
of recent findings showing that Ca2+-binding to calmyrin in
the calmyrin/aIIb complex induces subtle structural changes
that could further modulate the activity of aIIb [17]. This type
of Ca2+-regulation was already described for troponin
complex in vertebrate skeletal muscle, where Ca2+-binding
to troponin C constitutively associated with troponin I induces
conformational changes that activate the complex [21].
Therefore, it should be clarified in future studies whether
calmyrin binding to PS2 can contribute to signalling events
downstream of PS2 and whether Ca2+-binding to calmyrin in
calmyrin/PS2 complex can affect its structure and known PS2
activities.
Our studies indicate that while calmyrin and PS2 are
colocalized in some cell types such as lymphocytes, a
significant regulatory function of calmyrin for PS2 signaling
is hard to conceive in most brain neurons. In the light of low
calmyrin levels and limited overlap of the two protein
expression pattern, a probability for physical interaction of
the two proteins in forebrain neurons seems low. This is in
contrast to another PS2-interacting Ca2+-binding protein
calsenilin (called also Downstream Regulatory Element An-
tagonist Modulator, DREAM or Potassium Channel InteractingProtein, KChIP3), which expression pattern parallels PS2
staining in cerebellar and hippocampal neurons and is
consistent with calsenilin possible role as PS2 neuronal binding
partner [22]. Interestingly, association of endogenous calsenilin
and PS2 is also Ca2+-independent [23], leaving the question
regarding mechanism of a putative Ca2+-regulation of PS2 in
forebrain neurons open.
Another question that will be interesting to address in the
future arises from our finding that calmyrin is prominently
present in neurons of the medulla. Based on the relatively
high level of expression, it can be predicted that calmyrin
major function may be associated with this particular cell type
and its functional role deserves further investigation.
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